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Does ocular treatment of uveal melanoma influence survival?
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Treatment of uveal (intraocular) melanoma is aimed at prolonging life, if possible conserving the eye and useful vision. About 50% of
patients develop fatal metastatic disease despite successful eradication of the primary intraocular tumour. The effect of ocular
treatment on survival is unknown, because the same survival data from case series can be interpreted in different ways. Treatment is
therefore based on intuition and varies greatly between centres. Randomised trials of treatment vs non-treatment of asymptomatic
tumours are desirable but would be controversial, difficult, expensive and possibly inconclusive. Strategies for coping with uncertainty
are needed to avoid unethical care.
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It is widely believed that the primary reason for treating uveal
melanomas is to prevent metastatic spread of tumour from the
eye to other parts of the body. Despite successful eradication of
the ocular tumour, however, about 50% of all patients develop
metastatic disease, which is almost invariably fatal (Kujala et al,
2003). In this article, I discuss different ideas as so how treatment
of uveal melanomas influences survival. It is hoped that some of
the lessons learnt from the experience with these tumours will be
relevant to other fields of surgical oncology.
UVEAL MELANOMA
Epidemiology
Uveal melanomas have an incidence of approximately 2-8 per
million per year in Caucasians. An ophthalmologist in such
communities will see a new patient with this disease only rarely.
Presentation is at a median age of 60 years. Men and women are
affected in equal numbers. The disease is most common in
individuals with a fair complexion and a blue or grey iris colour.
The role of sunlight is uncertain.
More than 90% of uveal melanomas involve the choroid, causing
detachment of the overlying retina. The remainder are confined to
the iris and ciliary body and tend to cause cataract and glaucoma.
Most patients therefore present with blurred vision or visual field
loss. Advanced melanomas can make the eye inflamed and painful.
Extraocular extension into the orbit can occur at any stage.
Detection of uveal melanomas
In UK, about 30% of patients are asymptomatic at the time of
diagnosis, their tumour being detected on routine examination;
conversely, about 20% of symptomatic patients report that their
tumour was initially missed (Damato, 2001). Studies in other
countries such as Finland and the USA have reported similar
results (Eskelin and Kivela ¨, 2002; Bove and Char, 2004). In
addition, many patients experience delays in the referral process,
because of administrative shortcomings and diagnostic errors.
OCULAR TREATMENT OF UVEAL MELANOMA
Ocular treatment of uveal melanoma is termed ‘radical’ if it
consists of enucleation (i.e., ocular amputation) and ‘conservative’
if conservation of useful vision and the eye is attempted (Damato,
2006).
In most centres, the first choice of conservative treatment is
brachytherapy, delivered using plaque-shaped applicators contain-
ing isotopes such as iodine-125 or ruthenium-106, which emit
g- and b-irradiation respectively. The plaque is sutured to the
sclera overlying the tumour and removed days later once the
required dose of at least 80Gy has been delivered to the tumour.
Facilities for proton beam radiotherapy are becoming available in
a growing number of centres, some administering this treatment to
all patients and others reserving it for patients whose tumour is
considered unsuitable for brachytherapy. Stereotactic radiotherapy
is becoming more widespread in centres that are not able to
administer proton beam treatment.
After radiotherapy, many uveal melanomas become exudative,
causing visual loss from macular oedema and retinal detachment,
which if severe results in iris neovascularisation and painful
glaucoma (i.e., ‘toxic tumour syndrome’). These complications are
treated with intraocular injections of steroids or anti-angiogenic
agents or by administering phototherapy to the irradiated tumour
or removing it surgically.
En bloc tumour resection is widely performed for small iris and
ciliary body melanomas (i.e., iridectomy, iridocyclectomy, cyclec-
tomy); however, only a few surgeons excise large ciliary body and
choroidal melanomas (i.e., choroidectomy, cyclochoroidectomy).
This is because such surgery is technically difficult, also requiring
profound systemic hypotensive anaesthesia.
Choroidal melanomas can also be removed by ‘endoresection’,
which involves piecemeal tumour resection using a vitreous cutter
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into place with laser treatment. This operation is highly contro-
versial without neoadjuvant radiotherapy, because of concerns
about disseminating malignant cells around the eye and
systemically.
Small, pigmented choroidal melanomas can be treated by
transpupillary thermotherapy, whereby an infrared laser beam is
used to induce hyperthermia for about 60s. Photodynamic therapy
is still an investigational procedure but seems effective with some
small, amelanotic tumours.
Increasingly, multi-modality treatment is administered, for
example, performing tumour resection with adjunctive or neo-
adjuvant radiotherapy or combining radiotherapy with photo-
therapy.
Large naevi can be clinically indistinguishable from small
melanomas. It is accepted practice for such ‘suspicious naevi’
or ‘melanocytic tumours of indeterminate malignancy’ to be left
untreated until growth has been documented by sequential
ophthalmoscopy or ultrasonography.
Outcomes such as ocular conservation, visual preservation and
local tumour control depend greatly on the tumour size, proximity
to optic disc or fovea, extent of ciliary body or angle involvement,
presence or absence of extraocular spread and ocular morbidity
such as retinal detachment, glaucoma and cataract (Figure 1).
In specialist centres, ocular preservation is attempted in about
60–70% of patients and is successful in about 90% of these cases
(Damato and Lecuona, 2004). Actuarial rates of local tumour
recurrence range from less than 5% after plaque or proton beam
radiotherapy to approximately 10–15% after phototherapy or
transscleral choroidectomy especially. Some degree of useful vision
is preserved in most patients, if the tumour does not extend close
to disc or fovea.
Ocular treatment varies greatly between centres, not only
according to the expertise and equipment available in each centre
but also according to the rationale of treatment, which depends on
how treatment is believed to influence survival. For these reasons,
few randomised, controlled trials have been conducted to compare
one treatment with another so that most evidence is based on
case series.
METASTATIC DISEASE
Metastatic spread occurs haematogenously. About 90% of patients
with metastatic disease show hepatic involvement, other sites
including lung, skin, bone and brain. Death usually occurs within
a year of the onset of systemic symptoms (Eskelin et al, 2003).
Treatment by systemic or intra-hepatic chemotherapy or partial
hepatectomy only rarely prolongs life (Augsburger et al, 2009).
There is controversy about whether to screen for metastatic
disease and if so in whom and for how long. When screening is
undertaken, there is great variation in the methods used, with
some relying on blood tests and others performing imaging
consisting of ultrasonography, magnetic resonance imaging or
positron-emission tomography.
Because many patients already have micrometastases by the
time their ocular tumour treatment is detected and treated, some
groups have investigated various forms of systemic adjuvant
therapy in high-risk patients. No definite survival benefit has been
demonstrated although one study showed a non-significant trend
(Desjardins et al, 1998; Voelter et al, 2008).
ESTIMATING THE SURVIVAL PROGNOSIS
As with other cancers, estimation of the survival probability allows
patients with a good prognosis to be reassured about their life
expectancy while targeting special measures at high-risk patients.
Prognostication also allows patients with low risk of metastasis to
be excluded from studies evaluating the impact of ocular or
systemic treatment on survival, thereby enhancing the chances of
detecting any statistical significance in outcome.
Figure 1 (A) A 44-year-old man was referred with an inferonasal choroidal melanoma in the left eye, which had a visual acuity of 6/7.5. (B)O n
ultrasonography, the tumour had a collar-stud shape and measured 15.3mm in basal diameter, with a thickness of 11.2mm. (C) The patient underwent
transscleral local resection under hypotensive anaesthesia with adjunctive ruthenium plaque brachytherapy. (D) At 6 months postoperatively, the visual
acuity was 6/9.5. The melanoma was of spindle-cell type with no chromosome 3 loss shown by multiplex ligand-dependent probe amplification. These
findings indicate a minimal risk of metastatic disease and therefore a near-normal life expectancy.
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(1) basal tumour diameter; (2) ciliary body involvement;
(3) transscleral extension; (4) epithelioid melanoma cytomorpho-
logy; (5) high mitotic rate; (6) extravascular matrix patterns such
as closed loops; (7) microvascular density; (8) chromosome 3
deletion, chromosome 8q gain and lack of chromosome 6p gain
and (9) a class 2 gene expression (Prescher et al, 1996; White et al,
1998; Onken et al, 2004; Damato et al, 2007; Damato and
Coupland, 2009).
Survival studies have largely relied on clinical features for
prognostication, particularly the largest basal tumour diameter.
However, tumours having the same dimensions show significant
variation in survival according to their histological and genetic
features (Damato and Coupland, 2009). The author and associates
have therefore developed online neural networks for genera-
ting personalised survival curves using clinical, histological and
genetic predictors, also taking age and sex into account
(www.ocularmelanomaonline.com; Damato et al, 2008). Such
multivariate analysis has enhanced the reliability of prognostica-
tion so that it is relevant to individual patients.
Improvements in surgical, laboratory and statistical methods
have increased the scope of prognostication so that genetic tumour
typing is now being performed in a growing number of centres, not
only with tumours treated by enucleation or local resection but
also in patients undergoing radiotherapy or phototherapy. Such
patients may have transscleral or transretinal biopsy immediately
before or after treatment.
In the absence of a good treatment for metastatic disease,
opinions vary as to how much patients should be told about their
prognosis and hence whether tumour biopsy for prognostication is
justifiable.
EFFECT OF OCULAR THERAPY ON SURVIVAL
Hypothesis 1: timely enucleation prevents metastatic death
For more than a century, uveal melanomas were treated radically,
by urgent enucleation, so as to maximise any chances of survival. It
was generally accepted that ocular treatment successfully pre-
vented metastatic spread in many patients, particularly if the
treatment was performed early, when the tumour was still small.
Strong correlations between tumour size and metastatic death
supported this view (Figure 2).
Hypothesis 2: conservative forms of ocular treatment are
dangerous
Manschot, a vociferous Dutch pathologist, condemned radio-
therapy as unsafe and strongly recommended enucleation for all
patients (Manschot and van Strik, 1987). His advice was based on
the finding that viable tumour cells can be seen in most irradiated
melanomas. However, several non-randomised studies showed no
statistical difference between conservative and radical forms of
therapy. Conservative forms of therapy were generally considered
ethical if the patient was prepared to take a risk to avoid mutilating
surgery or visual handicap.
Hypothesis 3: ocular treatment accelerates metastatic
death
In 1978, Zimmerman, an eminent American pathologist, published
an influential article suggesting that enucleation (and by impli-
cation, other treatments) accelerated metastatic death by physi-
cally disseminating tumour cells from the eye into the general
circulation (Zimmerman et al, 1978). This hypothesis was based
largely on the observation that the mortality rate peaks in the
second post-operative year. Concerns about iatrogenic tumour
dissemination led to several preventative measures, such as pre-
enucleation radiotherapy. Some abandoned treatment altogether
unless the eye became painful.
Hypothesis 4: brachytherapy and enucleation are equally
effective
To resolve controversies about Zimmerman’s and Manschot’s
hypotheses, forty centres in North America undertook large,
randomised, multi-centre, collaborative ocular melanoma studies
(COMS). One of these studies investigated the impact of pre-
enucleation, external beam radiotherapy on survival in 1003 patients
with a large uveal melanoma (Hawkins, 2004). This trial concluded
that it found no survival advantage attributable to pre-enucleation
radiotherapy. The implication of this result was that Zimmerman’s
hypothesis was wrong and that traumatic dissemination of malignant
cells at the time of enucleation did not accelerate death. The most
plausible explanation for the observed peak in metastatic death in
the second post-operative year is the tendency for patients to present
when the tumour diameter is 13mm.
Another COMS trial involving 1317 patients compared survival
after iodine plaque radiotherapy with that after enucleation, in
patients with a medium-sized melanoma (Collaborative Ocular
Melanoma Study Group, 2006). Recruitment took longer than
expected because many patients were reluctant to lose their eye
when less disfiguring treatment was possible. Eventually, this
COMS trial concluded that there was no survival difference
between plaque radiotherapy and enucleation. This has been
widely taken to mean that plaque radiotherapy and by implication
other forms of conservative therapy are as safe as enucleation.
Hypothesis 5: delayed treatment and local treatment
failure increase mortality
Straatsma et al (2003) compared 43 untreated patients with
historical controls and reported a trend towards higher mortality
in patients who were not immediately treated; however, this result
may have been caused by selection bias as the patients with
deferred treatment tended to be older. Gragoudas et al (2002) have
shown local tumour recurrence after conservative treatment to be
associated with higher mortality, suggesting that the recurrences
shortened life, however, others countered this argument with the
suggestion that recurrences were merely an indictor of increased
tumour malignancy.
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Figure 2 Kaplan–Meier survival curves showing rates of metastatic
death according to basal tumour diameter after treatment of choroidal
melanoma. Patients were included only if residing in mainland UK and
if histological tumour type was known (from Damato and Coupland,
2009).
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type and not by treatment
In the 1990s, it was discovered that uveal melanomas tend to
develop several non-random chromosomal abnormalities, parti-
cularly chromosome 3 loss (monosomy-3) and gains in 6p and 8q.
In 1996, Prescher et al found that metastatic death occurred
exclusively in patients with a monosomy-3 melanoma. Later
studies reported that chromosome 3 loss and chromosome 6p
gain to be mutually exclusive (Parrella et al, 1999). The concept
arose that there are two distinct types of uveal melanoma:
lethal, monosomy-3 melanomas and non-lethal, disomy-3 mela-
nomas, the latter often showing chromosome 6p gain
(Tschentscher et al, 2003). Estimates of tumour doubling times
of metastases from uveal melanomas supported the hypothesis that
lethal melanomas metastasise when they are very small, several
years before the ocular tumour is detected and treated (Eskelin
et al, 2000). These inferences cast considerable doubts on the
efficacy of ocular treatment in prolonging life. The correlation
between tumour size and increased mortality (Figure 3) was
attributed to the higher prevalence of monosomy-3 in
large tumours rather than to any beneficial therapeutic effect
(Augsburger et al, 2007; Damato and Coupland, 2009). According
to this view, uveal melanomas become large after developing
monosomy-3 and not before so that correlations between size and
mortality reflect rate of tumour growth.
Proponents of this hypothesis argued that whether or not the
COMS conclusions were correct, they were statistically incon-
clusive because many patients had a non-lethal melanoma so that
the required statistical power was not achieved. According to this
reasoning, some studies evaluating systemic adjuvant therapy
would perhaps have shown a statistically significant benefit if
genetic tumour typing had been undertaken to exclude non-lethal
melanomas.
Hypothesis 7: ocular treatment prevents metastasis in
some patients
In 1998, White et al proposed that metastatic disease occurs rarely or
n o ta ta l lu n l e s sm o n o s o m y - 3a n dc h r o m o s o m e8 qg a i no c c u r
together (White et al, 1998). Subsequent multivariate analyses did not
support this (Damato et al, 2007; Ehlers et al, 2008). It was therefore
assumed by some that monosomy-3 was the lethal abnormality and
that chromosome 8q gain merely accelerated metastatic death,
possibly because of increased expression of the C-MYC gene.
Tentative data from recent studies, however, have supported findings
by White et al that metastatic death is rare except when chromosome
3 loss and 8q gain occur together (Damato et al, 2009).
It is not known how many tumours without chromosome 3 loss
and 8q gain at the time of treatment would have developed these
changes if left untreated. It is therefore not known how many lives
have been saved by timely treatment. In other words, after
studying the statistics given in Figure 2 one cannot estimate to
what extent survival is influenced by treatment. The concept of
‘crescendo malignancy’ is supported by intra-tumoral genetic
heterogeneity, which suggests an ongoing evolutionary process
(Dopierala et al, 2010). Furthermore, the author recently treated a
patient, whose tumour suddenly grew dramatically after several
years of apparent dormancy, making the eye blind and painful so
that enucleation was required (Callejo et al, submitted). Histology
and genetic studies showed the base of the tumour to consist of
low-grade, spindle-cell melanoma with only partial chromosome 3
loss whereas the apical region showed high-grade, epithelioid cells
with monosomy-3 and gains in chromosome 8q. This case suggests
late development of the metastatic genotype, which occurred while
the patient was being observed and which might have been
prevented by early treatment.
According to this hypothesis, there are three groups of uveal
melanoma: (1) metastasising melanomas, which have already
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Figure 3 Prevalence of choroidal melanomas with (A) epithelioid cells, (B) closed connective tissue loops, (C) high mitotic rate and (D) chromosome 3
loss, according to basal tumour diameter (from Damato and Coupland, 2009). HPF, high-power fields.
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metastases may not be detectable; (2) pre-metastasising melano-
mas, which develop metastatic capability and disseminate if
treatment is delayed and (3) non metastasising melanomas, which
do not metastasise, even if never treated.
Which hypothesis is correct?
It might seem that the various hypotheses are mutually exclusive, so
that if one endorses one view one must necessarily exclude all other
models. If uveal melanomas behave in a diverse manner, however,
with some metastasising early and others very late or not at all, then
more than one hypothesis may be correct and the seemingly rival
hypotheses may actually complement each other to some extent.
COPING WITH UNCERTAINTY
Uncertainty about the effect of ocular treatment on survival is
unsettling. On the one hand, there are concerns that many patients
might be sacrificing their vision and even the eye unnecessarily in
the hope of living longer; conversely, there are fears that patients
with a small melanoma might be dying of metastasis because
treatment is delayed until growth is documented.
Research
In theory, there is much scope for randomised trials of treatment
vs non-treatment of asymptomatic uveal melanoma, particularly
when ocular treatment is likely to cause severe ocular morbidity
(e.g., if the tumour extends close to optic disc or macula). These
studies would indicate whether ocular treatment prolongs life in
the case of metastasising melanomas (i.e., once metastatic spread
has already commenced), pre-metastasising melanomas or both. In
practice, there are many obstacles to such trials. First, there are
ethical concerns about the dangers of delaying treatment and
missing any opportunities for preventing metastasis. Second, it will
be difficult to recruit sufficient numbers of patients, because of the
rarity of uveal melanomas, particularly of asymptomatic tumours.
Third, much data will be lost because treatment becomes necessary
for ocular reasons soon after the patient is enrolled (e.g., if the
tumour grows or becomes symptomatic). Fourth, even if
sequential biopsy is achieved, it will be difficult to determine
whether any inconsistent results indicate tumour progression or
intra-tumoral heterogeneity.
For these reasons, randomised trials may not be conducted for
many years, if at all. In the meantime, multi-centre, prospective
cohort studies with matched, treated and untreated patients would
seem preferable to performing no investigation at all. If the tumour
histology and genetic studies were to be determined sequentially
by repeated biopsies, then such studies may reveal which tumours
progress without treatment and which do not. Prospective cohort
studies should also determine how many untreated patients
eventually require some form of intervention as well as providing
insights regarding the reasons for such therapy. Importantly, these
studies would show whether procrastination has any adverse
consequences in terms of mortality, visual loss, ocular conserva-
tion, psychological morbidity and cost.
Routine clinical practice
It is conventional procedure to obtain signed consent for surgery
but not for withholding treatment; however, in view of the
controversial nature of non-treatment, it would be prudent to
obtain written consent from patients whose treatment is deferred.
This should prevent subsequent recriminations in the event of
metastatic death or other untoward events.
Intuitively, patients tend to believe that surgical treatment of
cancer improves survival, but if there is no good scientific evidence
for such benefit then this should be explained to them; otherwise,
consent for treatment cannot be regarded as truly informed. It
would be wise to document that this communication has taken
place, especially if iatrogenic ocular morbidity is likely to occur.
As for the management itself, there seem to be few guidelines on
how to decide whether to administer treatment when the required
evidence is lacking. It is likely that there is much variation in clinical
practice. The author attempts to help patients select the management
that best fits their wishes and attitude to risk. This can be difficult,
especially when there is equipoise between observation, photother-
apy, radiotherapy, endoresection and enucleation, as is often the case
with small, juxtapapillary melanocytic tumours of indeterminate
malignancy. A CD-ROM of the actual conversation is given to the
patient to help remember what was said. Some patients express
bemusement that they travel a long distance to seek the advice of an
‘expert’ only to be told that they must make up their own minds on
what to do about their tumour.
CONCLUSIONS
Formidable logistical and ethical obstacles have prevented
randomised controlled trials of treatment vs non-treatment of
uveal melanoma. It has therefore been necessary to rely on case
series, whose results have given rise to a bewildering variety of
hypotheses. Because of the lack of good evidence, practitioners and
patients rely on intuition. For example, some opinion leaders
consider endoresection of choroidal melanoma to be dangerous if
not preceded by radiotherapy (Bechrakis et al, 2004). This is
perhaps because they regard metastatic spread of this cancer to be
a mechanistic process, with surgical trauma disseminating
malignant cells. Such allegorical thought probably formed the
basis of Halsted’s mutilating radical mastectomy, with breast
cancer being compared to a weed with long roots, all of which had
to be dug out entirely if any success was to be achieved.
Uncertainty regarding the impact of ocular treatment on
survival has ethical implications, particularly about informed
consent for treatment.
There is still much to learn about how best to cope with
uncertainty about therapeutic benefit.
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